ImmuPharma (LON:IMM) Trading Up 11.2% – Still a Buy?

ImmuPharma plc (LON:IMM)’s stock price was up 11.2% during mid-day trading on Saturday . The company traded as high as GBX 2.66 ($0.04) and last traded at GBX 2.28 ($0.03). Approximately 13,502,244 shares changed hands during trading, an increase of 102% from the average daily volume of 6,691,796 shares. The stock had previously closed at GBX 2.05 ($0.03).

ImmuPharma Trading Up 11.2%

The firm has a market cap of £9.69 million, a price-to-earnings ratio of -3.94 and a beta of 1.53. The stock has a 50-day moving average of GBX 2.52 and a 200-day moving average of GBX 3.05.

ImmuPharma (LON:IMM) last announced its quarterly earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.